New vaccine trial aims to shield korean babies from deadly meningitis

NCT ID NCT06113198

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the MenB+OMV NZ vaccine in 50 healthy infants starting at 2 months old in South Korea. The vaccine is given as three shots over about a year to see if it triggers a strong immune response against meningococcal group B bacteria, which can cause meningitis. Researchers will also monitor for any side effects. The goal is to confirm the vaccine works well and is safe for this age group in Korea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MenB+OMV NZ vaccine
What this could lead to
If successful, this could confirm that the vaccine protects Korean infants against meningococcal group B disease, a serious cause of meningitis.
What could go wrong
This is a small, single-arm study with only 50 participants, so results may not apply broadly. Side effects like fever or injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGITIS, MENINGOCOCCAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GSK Investigational Site

    Incheon, 6510, South Korea

  • GSK Investigational Site

    Junggu, 400711, South Korea

  • GSK Investigational Site

    Kyungki-do, 14068, South Korea

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, 13620, South Korea

  • GSK Investigational Site

    Seoul, 02841, South Korea

  • GSK Investigational Site

    Seoul, 05505, South Korea

  • GSK Investigational Site

    Seoul, 07804, South Korea

  • GSK Investigational Site

    Seoul, 137701, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.